How To Detect Alzheimer’s 30 years In Advance

Scientists from Japan and Australia have teamed up to develop and validate a blood test for Alzheimer’s disease, with the potential to massively ramp up the pace of Alzheimer’s disease drug trials. The blood test measures a specific peptide in the blood to inform scientists, with 90 per cent accuracy, if a patient has the very earliest stages of Alzheimer’s diseaseBlood samples from patients in a large study from the Japanese National Center for Geriatrics and Gerontology (NCGG) were initially analysed to identify the relevant peptides. Those indicating brain beta-amyloid burden were then tested against patient samples from the Australian Imaging, Biomarker and Lifestyle Study of Aging (AIBL), to validate the results.


Our study demonstrates the high accuracy, reliability and reproducibility of this blood test, as it was successfully validated in two independent large datasets from Japan and Australia.” says Professor Katsuhiko Yanagisawa, Director-general of Research Institute at NCGG.

Dr Koichi Tanaka at Shimadzu Corporation was instrumental in developing the initial blood testing procedure. Professor Tanaka won the Nobel prize in Chemistry in 2002 for the technique. “From a tiny blood sample, our method can measure several amyloid-related proteins, even though their concentration is extremely low. We found that the ratio of these proteins was an accurate surrogate for brain amyloid burden.”

One of the essential hallmarks of Alzheimer’s disease is buildup of abnormal peptide in the brain, called beta-amyloid. The process starts silently about 30 years before outward signs of dementia, like memory loss or cognitive decline, have begun.

Current tests for beta-amyloid include brain scans with costly radioactive tracers, or analysing spinal fluid taken via a lumbar puncture. These are expensive and invasive, and generally only available in a research setting. A diagnosis is usually made without these tools, by assessing a patient’s range of symptoms.

Laureate Professor Colin Masters of the Florey Institute of Neuroscience and Mental Health, and The University of Melbourne, has been at the forefront of Alzheimer’s research since the 1980s. Professor Masters, who co-led the research published in the latest issue of Nature, comments: “This new test has the potential to eventually disrupt the expensive and invasive scanning and spinal fluid technologies. In the first instance, however, it will be an invaluable tool in increasing the speed of screening potential patients for new drug trials.


How To Prevent Metastasis In Pancreatic Cancer

UCLA scientists have unlocked an important mechanism that allows chemotherapy-carrying nanoparticles—extremely small objects between 1 and 100 nanometers (a billionth of a meter)—to directly access pancreatic cancer tumors, thereby improving the ability to kill cancer cells and hence leading to more effective treatment outcome of the disease. The researchers also confirmed the key role of a peptide (an extremely small protein) in regulating vascular access of the nanoparticle to the cancer site.

The discovery is the result of a two-year study co-led by Drs. Huan Meng and André Nel, members of UCLA‘s Jonsson Comprehensive Cancer Center and the UCLA California NanoSystems Institute. The findings are important as they demonstrate how the delivery of chemotherapy to pancreatic cancer can be improved significantly through the use of smart-designed nanoparticle features.

Pancreatic ductal adenocarcinoma is generally a fatal disease, with a five-year survival rate of less than 6 percent. The introduction of nanocarriers as delivery vehicles for common chemotherapy agents such as the drug irinotecan, has led to improved survival of patients with this disease. However, the reality is that nanocarriers may not always reach their intended target in sufficient numbers because of a constraint on their ability to transit through the blood vessel wall at the tumor site, leading the encapsulated drugs to be diverted or lost before they can deliver their payload.

silica nanoparticle

A key challenge for scientists is how to help nanoparticles travel to and be retained at tumor sites. This can be accomplished by custom-designed or engineered nanoparticles that overcome common challenges, such as the presence of a dense tissue surrounding the pancreas cancer cells. Prior research has identified a major vascular access mechanism that relies on a vesicle transport system, which can be turned with a peptide called iRGD in the blood vessel wall. iRGD is therefore potentially useful to optimize the delivery of cancer drugs by the nanoparticle to the tumor.

The UCLA research team designed a nanoparticle comprised of a hollow silica core surrounded by a lipid bilayer to enhance the delivery of irinotecan in an animal model with pancreatic cancer. The invention is called a silicasome. The researchers proposed that the therapeutic benefit of the irinotecan containing nanoparticles may be enhanced when combined with the injection of iRGD. The investigators used the nanoparticle plus the iRGD to deliver irinotecan in a robust animal model for pancreatic cancer that closely mimics human disease.

The study is published online in the Journal of Clinical Investigation.


Li-Ion Batteries Mimick Shells To Last Longer

Scientists are using biology to improve the properties of lithium ion batteries. Researchers at the University of Maryland, Baltimore County (UMBC) have isolated a peptide, a type of biological molecule, which binds strongly to lithium manganese nickel oxide (LMNO), a material that can be used to make the cathode in high performance batteries. The peptide can latch onto nanosized particles of LMNO and connect them to conductive components of a battery electrode, improving the potential power and stability of the electrode.

Biology provides several tools for us to solve important problems,” said Evgenia Barannikova, a graduate student at UMBC. Barannikova works in the lab of Mark Allen and studies how biological molecules in general can improve the properties of inorganic materials in batteries.

Biology provides several tools for us to solve important problems,” said Evgenia Barannikova, a graduate student at UMBC. Barannikova works in the lab of Mark Allen and studies how biological molecules in general can improve the properties of inorganic materials in batteries.
By providing a new nanoscale architecture for lithium-ion batteries, the researchers say that the approach could improve the power and cycling stability of lithium-ion batteries.
The researchers will present their results at the 59th annual meeting of the Biophysical Society, held Feb. 7-11 in Baltimore, Maryland.